New drug aimed at taming Immunotherapy's stubborn side effects
NCT ID NCT05660421
First seen Apr 28, 2026 · Last updated May 02, 2026 · Updated 1 time
Summary
This study was designed to see if the drug itacitinib can help people whose immune system overreacts to cancer immunotherapy, causing side effects that steroids can't fix. It was planned for adults with certain cancers who had these stubborn side effects. However, the study was withdrawn before any participants enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.